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Abstract: Major depressive disorder (MDD) is a common and serious illness of our times, 
associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, 
  possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older 
antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing 
rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake 
inhibitors and newer antidepressants, which have dual modes of action such as inhibition of 
the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have 
additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs 
in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin 
reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have 
similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treat-
ment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of 
available antidepressants, there are still at least 30% of depressive patients who do not benefit 
from treatment. Therefore, new approaches in drug development are necessary and, according 
to current research developments, the future of antidepressant treatment may be promising.
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Introduction
Major depressive disorder (MDD) is a common and serious illness with the potential 
of becoming the leading cause of disability worldwide.1 The lifetime prevalence rate 
is 16.2%, and is expected to increase.2,3 In the elderly, prevalence is about 3% in the 
general population4 and 15%–25% among nursing home residents.5 These numbers 
may be even higher, because it is estimated that clinically significant depression goes 
untreated in 60% of the elderly.6 The average age of onset of MDD is the mid-20s.3 
The lifetime risk in women is twice the risk in men, and is increased during the 
reproductive years.3
The illness is described by a wide range of symptoms, such as disturbances in sleep, 
appetite, sexual desire, and constipation. It is also characterized by crying, sadness, 
and loss of the ability to experience pleasure in work or with friends. Depression is 
strongly associated with suicidal events, cognitive abnormalities, impaired memory 
function, and slowing of speech and action.7 Furthermore, patients with MDD often 
have painful physical symptoms.8 If symptoms which interfere considerably with 
activities of daily living and domestic relationships persist for more than two weeks, 
MDD should be considered.7Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Mechanisms of disease
MDD is a complex disorder, probably influenced by genetic 
and environmental factors. Heritability of   depression has been 
estimated to range from 30% to 40%.3 The   polymorphisms 
associated with the serotonin transporter gene9 have 
been related to more depressive symptoms, diagnosable 
  depression, and tendency to commit suicide.3,10 Nevertheless, 
the relationship between genetics and depression is probably 
very complex and not fully elucidated.7
Some environmental factors, such as stress, could pre-
dispose to depression by affecting the genome.7,9 Personality 
characteristics may predict an individual’s susceptibility 
to depression, but personality may also be modified in the 
disease. Moreover, personality may alter the clinical presen-
tation of a depressive disorder.11
Monoamine deficiency hypothesis
The monoamine hypothesis of depression postulates a defi-
ciency in monoaminergic neurotransmission in the brain, 
mediated by serotonin and noradrenaline. Noradrenaline 
depletion may be due to inhibition of tyrosine hydroxylase 
(see Figure 1), whereas reduced synthesis of serotonin may 
be due to depletion of dietary tryptophan or mutations of 
tryptophan hydroxylase.7,12 Given that reduced serotonin 
levels do not cause depression in all people, it is unclear if 
decreased serotonin synthesis is a cause or consequence of 
depression.9
Deficiency in monoaminergic neurotransmission may be 
caused by disturbed receptor signaling, even with   normal 
monoamine levels. Decreased sensitivity of 5-HT1A and 
5-HT1B autoreceptors, which regulate serotonin   function, 
has been associated with depression.13,14 In contrast, the 
sensitivity of α2-noradrenergic receptors, which modu-
late   noradrenaline release by feedback inhibition, was 
enhanced in depressed patients.15 Moreover, disturbed 
receptor   signaling could also be a result of malfunction 
of G-protein or   secondary   messenger systems, which may 
impair   neurotransmitter   function, even without changes in 
monoamine levels or receptor numbers.7 Decreased levels 
of secondary   messengers, such as inositol,7,16 cAMP,7,17 and 
cAMP response element-binding protein, have been reported 
in the brains of patients with MDD at autopsy.7,18
The monoamine deficiency hypothesis is supported by 
the fact that noradrenaline and serotonin reuptake inhibitors 
have antidepressant activity. Nevertheless, only 50%–70% of 
patients respond to these drugs, implicating a more   complex 
mechanism for depression.7,19 Furthermore, dopamine 
  deficiency has been associated with the disease as well. 
Such a hypothesis is supported by the antidepressant activity 
of dopamine reuptake inhibitors and dopamine agonists.7
Stress, hypothalamic-pituitary-adrenal 
axis, and growth factors
Stress is perceived by the brain cortex and transmitted to the 
hypothalamus, where corticotrophin-releasing hormone is 
produced and released, leading to further elevation of cortisol 
plasma levels. The hypothalamic-pituitary-cortisol hypoth-
esis postulates that depression is associated with elevated 
cortisol levels in response to stress.20,21 However, doubt was 
cast on this hypothesis by disappointing results in clinical 
trials with corticotrophin-releasing hormone antagonists.22 
It is also difficult to establish the relationship between stress 
and depression, given that stress may be both the cause and 
consequence of depressed mood.7
It was suggested that elevated levels of glucocorticoids 
may reduce neurogenesis and lead to decreased size of the 
hippocampus in some depressed patients.23 Stress and cortisol 
may affect and decrease hippocampal levels of brain-derived 
neurotrophic factor, necessary for axonal growth, neuronal 
survival, and synaptic plasticity.24–26 Reduced brain-derived 
neurotrophic factor levels were found in the hippocampi of 
depressed patients.24
Other possible disease mechanisms
Other theories about the pathophysiology of depression 
include changes in glutamatergic neurotransmission,25 reduced 
neurotransmission gamma-butyric acid,26 abnormal circadian 
rhythms,27 deficient neurosteroid synthesis,28 impaired 
endogenous opioid function,29 monoamine-  acetylcholine 
imbalance,30 tyroxine abnormalities,31 and dysfunction of spe-
cific brain structures and circuits.32 Many of these mechanisms 
are involved in other psychiatric and neurologic disorders, but 
the impact on MDD is still unclear.
Traditional therapy
The most common nonpharmacologic approach for treating 
MDD is psychotherapy. It is especially helpful in patients 
with a history of childhood adversity or recent stress.33 
  Psychotherapy and medication were shown to be comparable 
for unipolar depression, and it was suggested that psycho-
therapy may offer a prophylactic advantage compared with 
medication.34 Other possible approaches include neurostimu-
lation techniques, electroshock, or electroconvulsive therapy, 
indicated only for treatment of resistant depression.9
Traditional pharmacotherapy includes tricyclic antidepres-
sants (TCAs) and monoamine oxidase inhibitors (MAOIs). Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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However, selective serotonin reuptake   inhibitors (SSRIs) and 
newer antidepressants are considered as “  first-line” treatment.
Monoamine oxidase inhibitors
MAOIs inhibit MAO-A and MAO-B and reduce monoamine 
degradation. Phenelzine, isocarboxazid and tranylcyprom-
ine are irreversible nonselective inhibitors, and their effect 
may persist for weeks until the regeneration of MAO. The 
use of MAOIs is decreasing due to serious side effects, 
such as acute hypertensive reactions after consumption of 
tyramine-rich foods, eg, aged cheese.35 These drugs have 
severe, potentially life-threatening interactions with many 
drugs, including meperidine, SSRIs, narcotic medications, 
and pseudoephedrine.36 Newer MAOIs inhibit the MAO 
enzyme reversibly. Moclobemide inhibits MAO-A, and does 
not require strict dietary restrictions.39 Selegiline inhibits 
MAO-B, and its transdermal formulation provides several 
advantages compared with orally administered MAOIs, 
including freedom from dietary tyramine restrictions and a 
better adverse effect profile.37
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Figure 1 The monoamine deficiency hypothesis.
Abbreviations: MAO-A, monoamine oxidase A; PLC, phospholipase-C; AC, adenylate cyclase; 1P3, ionsitol trisphosphate; PKC, protein kinase c; DAG, diacylglycerol;   
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Tricyclic antidepressants
The mechanism of action of most TCAs is noradrenaline 
and serotonin reuptake inhibition.38 They also antagonize 
  post-synaptic histamine H1, α1, 5HT2A, and muscarinic 
receptors.41 Following oral administration, TCAs are rapidly 
absorbed. They are highly (90%–95%) bound to plasma 
albumin, and have large distribution volumes.41 Metabolism 
occurs primarily by CYP450 (CYP2D6, CYP2C9, CYP2C19, 
and CYP3A4), and metabolites are renally excreted.41 
TCAs may interact with SSRIs by inhibition of CYP450 
isoenzymes. Concurrent use of fluoxetine or paroxetine can 
enhance TCA concentrations.41 Concurrent use of imipramine 
and clomipramine with MAOIs may cause pharmacodynamic 
interactions leading to serotonin syndrome.41 Although 
widely used in clinical practice, combinations of TCAs with 
MAOIs and SSRIs are generally considered to be unsafe.41 
TCAs have a small therapeutic range, and therapeutic drug 
monitoring is useful.39 Female gender and higher drug doses 
increase the risk of side effects.40
TCAs were shown to be comparable or more effective 
than SSRIs, but less well tolerated.41 Their advantage may 
be efficacy in treatment-resistant depression.42 Nortriptyline, 
a potent noradrenaline reuptake inhibitor showed superior 
pharmacologic properties compared with other TCAs.41 
Nortriptyline was better tolerated and may be administered 
concomitantly with MAOIs or SSRIs.41 Clomipramine may 
be the most efficacious TCA in severe depression.41 Ami-
triptyline is considered very effective, whereas dothiepin 
has the highest toxicity among the TCAs.41The more typical 
atropinic side effects of TCAs41 are presented in Table 1. 
Enhanced and toxic concentrations of TCA cause serious 
adverse effects, such as prolonged intracardiac conduction 
and postural hypotension.41,43
Selective serotonin reuptake inhibitors
SSRIs selectively inhibit neuronal reuptake of serotonin, 
with no significant affinity for histamine, acetylcholine, 
or adrenergic receptors. The most frequently used SSRIs 
in the treatment of depression are fluoxetine, fluvoxamine, 
sertraline, paroxetine, citalopram, and escitalopram.43 These 
agents have similar efficacy and tolerability.44 However, due to 
pharmacokinetic differences, they are not interchangeable.45 
Sertraline and citalopram show linear pharmacokinetics in 
contrast with fluoxetine, fluvoxamine, and paroxetine. SSRIs 
are usually characterized by slow elimination, and it takes 
time to achieve steady state.47 Fluoxetine has a half-life of 
1–4 days and its active metabolite norfluoxetine 7–15 days. 
Other SSRIs have shorter half-lives of 1–2 days and no 
clinically significant active metabolites.47 SSRIs are exten-
sively metabolized and show high interindividual variability.47 
Fluoxetine and norfluoxetine are inhibitors of CYP2D646,47 
and CYP3A4.46 Paroxetine inhibits CYP2D6,47–49 while 
fluvoxamine inhibits CYP1A2 and CYP2C19.48,49 As a 
consequence, their potential to interact with antipsychotics, 
opioids, and serotonin-norepinephrine reuptake inhibitors is 
high.48 Clinically significant interactions are more likely to 
occur with fluvoxamine, fluoxetine, and paroxetine compared 
with citalopram, escitalopram, or sertraline.48
Drug interactions with MAOIs, TCAs, moclobemide, 
tryptophan, lithium, and selegiline, as well as SSRI over-
doses, may lead to the serotonin syndrome, characterized by 
change in mental status, myoclonus, restlessness, hyperre-
flexia, shivering, diaphoresis, tremor, and possibly death.47,48 
SSRIs cause fewer side effects, such as dry mouth, consti-
pation, and blurred vision, and have a safer cardiac adverse 
event profile than the TCAs.47,48 Common adverse effects of 
SSRIs are listed in Table 1.
Paroxetine is a more potent noradrenaline inhibitor com-
pared with the other SSRIs and has the highest affinity for 
cholinergic receptors causing typical anticholinergic adverse 
effects.48 Sertraline significantly blocks dopamine reuptake, 
which may result in cardiovascular and extrapyramidal 
symptoms.48 Fluoxetine and sertraline have high dopamin-
ergic affinity that may also cause extrapyramidal symptoms. 
Citalopram has the highest affinity for H1 receptors of all 
the SSRIs, and may have weak antihistaminic activity at 
high doses.47,48 Despite these adverse effects, SSRIs remain 
reasonably well tolerated.44,48
Newer antidepressants
Newer antidepressants are usually characterized by a dual 
mode of action, such as inhibition of serotonin, noradrenaline, 
and dopamine reuptake. The pharmacokinetics, efficacy, and 
adverse effects of the newer antidepressants will be discussed 
in detail.
Escitalopram
Escitalopram is the most 5-HT transporter-selective com-
pound and the S-(+)-enantiomer of citalopram.47 Both 
SSRIs share similar pharmacokinetics.22 Following oral 
administration, escitalopram is rapidly and almost completely 
absorbed.48,49 The process is not affected by food.55 The 
pharmacokinetic profiles of the newer antidepressants are 
summarized in Table 2. Escitalopram is widely distributed 
throughout tissues,55,56 has low protein binding , and is not 
likely to have interactions with highly protein-bound drugs.55 Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Efficacy and adverse effects of triciclyc antidepressants, serotonin reuptake inhibitors and newer antidepressants
Drug and  
treatment dose
Efficacy Common adverse effects
TCAa More efficient than placebo,  
comparable efficacy to SSRIb
Dry mouth, blurry vision, constipation, urine retention, 
tachycardia, sedation and memory impairment 
progressing to delirium, seizures and death.40
SSRIb More efficient than placebo, comparable efficacy to TCAa Nausea, diarrhea, insomnia, headache, tremor, 
nervousness and sexual dysfunction.47,50,51
Escitalopram 
10–20 mg/day
Reponse after 8 weeks 56% in severe depression  
(MADRSc $ 30).69
Response after 8 weeks 82.6% and remission 66%  
after 6 months in severe MDDd (MADRSc)72 Response  
and remission of escitalopram 62.1%–68.3% and  
51.6%–57.8%, respectively after 8 weeks (MADRSc)73,75
Possibly more effective than duloxetine, fluoxetine, 
fluvoxamine, paroxetine, and reboxetine77
Escitalopram may be suitable in moderate to severe major 
depression and in adolescents.
Nausea (15%), insomnia (9%), sexual dysfunction (9%), 
diarrhea (8%), dry mouth (6%) agitation/restlessness, 
daytime sedation.45
Possibly better tolerated than duloxetine, paroxetine, 
raboxetine, sertraline, fluvoxamine and venlafaxine.77
Adverse event withdrawal rate 3%–7%.67,72
Mirtazapine 
15–60 mg/day
Responder rate 50%–73% according  to HAM-De within  
6 months.102,109-111.
Possibly better efficacy than duloxetine, fluoxetine, 
fluvoxamine, paroxetine and reboxetine.77
Mirtazapine may be superior to SSRI  
and venlafaxine in the acute phase.113
Drowsiness, sedation, insomnia, agitation, restlessness, 
headache, vertigo, appetite disturbances, changes in 
body weight, dry mouth, constipation, fatigue.103
Possibly better tolerated than reboxetine, fluvoxamine, 
duloxetine amitriptyline possibly less well tolerated 
than bupropion, citalopram, escitalopram, sertraline, 
venlafaxine.77,114
Discontinuation due to adverse effects 4%–5%.108,109
Bupropion IR 
200–450 mg/day 
Bupropion XR  
150–450 mg/day 
Bupropion SR  
150–400 mg/ day
Similar efficacy as TCAa and fluoxetine.134–136,140
Higher remission rates of bupropion (46%) vs venlafaxine  
(33%) and similar responder rates (HAM-De, MADRSc) 
after 6–8 weeks treatment.143,144
Bupropion may be suitable to augment citalopram and  
in major depressions.146,150
Bupropion IR: tremor (22%), menstrual complaints 
(5%), hypertension and impaired sleep (4%).150
Bupropion SR, XR: headache (22%–24%), dry 
mouth (13%–16%), sweating (4%–11%), constipation 
(5%–10%), nausea (9%–10%).132,143
Discontinuation rates due to adverse events 
5%–11%.118
Seizures, allergic reactions
Venlafaxine IR 
75–375 mg/day 
Venlafaxine ER 
75–225 mg/day
At least as effective as TCAa and probably more effective 
than SSRIb.168
Similar efficacy as sertraline and escitalopram.73,75,169 
Response odds ratio (1.15) and remission odds ratio 
(1.19) greater in venlafaxine compared to pooled data 
from fluoxetine, paroxetine, sertraline, citalopram, 
escitalopram and fluvoxamine.168 Remission rates of 
venlafaxine 45%, after 6–8 weeks.170
Possibly more efficacious than duloxetine, fluoxetine, 
fluvoxamine, paroxetine and reboxetine.77
Nausea, diarrhea, nervousness, sweating, dry mouth, 
muscle jerks, sexual dysfunction, blood pressure 
increase.45,177
Withdrawal rate due to adverse effects 9%.75
Discontinuation syndrome: nausea insomnia, chills, 
irritability and paresthesias.
Possibly better tolerated than reboxetine, fluvoxamine, 
duloxetine, TCA.77
Poorer tolerability than bupropion, citalopram, 
escitalopram, sertraline.77
Desvenlafaxine 
50–100 mg/day
More efficient than placebo at doses of 50 and 100 mg  
according to HAM-De scores after 8 weeks. Response  
and remission rates of desvenlafaxine were 53%  
and 32% respectively.175,182 No signifficant difference  
in efficacy between 50 and 100mg.175
Nausea, diarrhea, constipation, dry mouth, insomnia,  
decreased appetite, hyperhidrosis and dizziness  
($10%)175 ; less common: nervousness, tremor,  
and increased blood pressure (2%).45,183
Withdrawal rates due to adverse events 4%–8%.183
Duloxetine 
40–120 mg/day
Remission rates in patients with severe MDDd: 35.9%.201 
Response and remission rates: 58% and 48%, respecitvely, 
after 8 weeks.204 Similar efficacy to venlafaxine after 6 
weeks treatment.202
Possibly less efficacious than escitalopram, mirtazapine, 
sertraline and venlafaxine.77
Nausea, dry mouth, constipation, insomnia, dizziness, 
fatigue, diarrhea, somnolence, increased sweating, 
decreased appetite (.5%).206
Minimal effect on body weight208, modest effect on 
blood pressure and heart rate209, increased incidence 
of sexual dysfunction.210 Better tolerated than 
reboxetine.
Possibly less well tolerated than bupropion, citalopram, 
escitalopram and sertraline.77 Withdrawal rates due to 
adverse events 17%.204
(Continued)Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Escitalopram is   extensively metabolized in the liver via oxida-
tive metabolism.50,55 In the brain, metabolism of   escitalopram 
propionate may be mediated by MAO-A, MAO-B, and 
aldehyde oxidase.51,52 Nevertheless, the   metabolites do not 
contribute appreciably to therapeutic activity.
Escitalopram is a weak inhibitor of CYP isoenzymes 1A2, 
2C9, 2D6, and 3A4, and may have a low potential for clinically 
significant interactions with substrates for these isoenzymes.55 
Ritonavir, a potent CYP3A4 inhibitor, showed no effect on 
escitalopram pharmacokinetics.53 In contrast, cimetidine and 
omeprazole increased escitalopram exposure, but the effect is 
probably not of clinical concern.54 Concomitant administration 
of escitalopram with MAOIs or other SSRIs should be avoided 
because of possible serotonin syndrome.55
The elimination half-life is relatively short compared 
with other SSRIs, and steady-state plasma concentrations are 
achieved in a week.56 The main elimination route is renal.55
Escitalopram shows linear and dose-proportional pharma-
cokinetics in the dose range 10–30 mg/day.55,56 No reduction 
of citalopram dosage seems to be necessary in patients with 
moderately impaired renal function, but may be appropriate 
in patients with impaired hepatic function.55 Age and gender 
showed no clinically significant influence on escitalopram 
pharmacokinetics.55,56 Risk factors which may necessitate 
dose adjustment are presented in Table 3.
Escitalopram may be a suitable first-line antidepressant 
in moderate to severe major depression57 and in treatment of 
depression in adolescents.58 The drug was shown to be more 
efficacious than placebo and as least as effective or better 
than citalopram,22,66–69 with an early onset of efficacy.22,59 
Differences between the two SSRIs seem to depend on the 
initial severity of the depressive symptomatology, given that 
escitalopram has shown superior antidepressive efficacy in 
severely depressed patients.60,70 Nevertheless, opposite find-
ings were also reported, suggesting methodologic flaws as a 
cause for the difference in efficacy between the two drugs.60 
Efficacy scores for newer antidepressants are presented in 
Table 1.
Escitalopram showed similar efficacy to sertraline61 
and superior efficacy to paroxetine, especially in severely 
Table 1 (Continued)
Drug and  
treatment dose
Efficacy Common adverse effects
Milnacipran 
100–200 mg/day
Reponse to treatment after 8 weeks 65% at dose  
50 mg/day (HDRS).222 Response rate 58.9% MADRSc  
and 59.7% HAM-De.222,224
Possibly less efficacious than mirtazapine, escitalopram, 
venlafaxine, sertraline and citalopram. Possibly more 
efficacious than bupropion, duloxetine, fluvoxamine, 
paroxetine, fluoxetine and reboxetine.77
Nausea, nervousness, constipation, vertigo (5%), 
anxiety (4%), hot flushes (3%), dysuria (2%), dizziness, 
sweating (4%).45,226
Possibly better tolerated than TCA, reboxetine,  
fluvoxamine, fluoxetine, mirtazapine, venlafaxine, 
duloxetine, paroxetine.77,225 and possibly less well 
tolerated than bupropion, citalopram, escitalopram, 
sertraline.77
Reboxetine 
4–10 mg/day
Response rate in 27 patients with MDDd, 74% after 
6 weeks according to HAM-De.242 In severe MDDd 
responder rate with reboxetine were 56%–74% after  
4–8 weeks.243 Relapse rates afte 46 weeks were 22% 
(HAM-D)e.244
Possibly less efficacious than bupropion, citalopram, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, 
milnacipran, mirtazapine, paroxetine, sertraline, 
venlafaxine.77
Dry mouth, insomnia, headache, constipation, 
sweating, nausea, dizziness, anorexia and asthenia 
(.5%).240
Male patients: tachycardia, urinary retention or 
hesitancy, impotence and sexual dysfunction.240 
Frequency of discontinuation was 10%.245
Possibly less well tolerated than bupropion, citalopram, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, 
milnacipran, mirtazapine, paroxetine, sertraline, 
venlafaxine.77
Agomelatine 
25–50 mg/day
Response to treatment was 56%–63% and remission 30% 
after 8 weeks (HAM-De.255 Response rate 49% (HAM-De) 
and improvement in CGI-Sf after 6 weeks was reported, 
remission rate 21%.254
Nausea dizzines (9%), dry mouth, diarrhea 
nasopharyngitis (7%) and influenza (7%).250,254
absence of serotonin syndrome, weight gain and low 
incidence of sexual dysfunction and gastrointestinal 
side effects.250
Aripiprazole 
2–5 mg/day
Remission rates with adjunctive aripiprazole to standard 
antidepressant treatment vs placebo 25.4% vs 15.2%, 
response rates 32.4% vs 17.4% respectively after 6 
weeks.262 Mean change in MADRSc total score was 
significantly greater with adjunctive aripiprazole -8.8 than 
adjunctive placebo -5.8 after 6 weeks.261
Akhatisia (23%), nausea (3%), insomnia (8%), 
restlessness (14%), upper respiratory tract infections 
(8%), weight gain.261, 262
Abbreviations: TCA, tricyclic antidepressants; SSRI, selective serotonin reuptake inhibitors; MADRS, Montgomery Asberg Depression Rating Scale; MDD, major 
depressive disorder; HAM-D, Hamilton Rating Scale for Depression; CGI-S, Clinical Global Impressions-Severity of illness scale.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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depressed patients.62 Furthermore, in short-term studies, 
superior efficacy of escitalopram compared with citalopram, 
paroxetine, and duloxetine was observed.63
The efficacy of escitalopram was similar to that of 
venlafaxine, but there was a trend of higher response and 
remission rates in the escitalopram group.64,65 The SSRI may 
be at least as effective as venlafaxine and duloxetine even 
in severe depression.66
Cipriani et al reported superior efficacy of escitalopram 
over duloxetine, fluoxetine, fluvoxamine, paroxetine, and 
reboxetine. Following mirtazapine, escitalopram was the 
most efficacious drug among 12 antidepressants.67
The prominent side effects of escitalopram are similar 
to those of other SSRIs (see Table 2).46 Similar tolerability 
and withdrawal rates for citalopram and escitalopram were 
reported.22,67–69 In contrast, escitalopram (10–20 mg/day) 
showed better tolerability in long-term treatment than par-
oxetine. The most common adverse event with escitalopram 
was headache, and nausea with paroxetine.74 Moreover, 
nausea, sweating, and obstipation were significantly less 
frequent compared with venlafaxine.22,68 Cipriani et al 
reported better tolerability of escitalopram compared with 
duloxetine, paroxetine, reboxetine, sertraline, fluvoxamine, 
and venlafaxine.79
Doses of 10–20 mg/day showed consistent antidepressive 
efficacy and excellent tolerability in primary care patients 
with MDD.68 The recommended starting dose of 10 mg/day 
is appropriate for most patients regardless of age, gender, or 
mild to moderate renal impairment or hepatic insufficiency.55 
A period of at least four weeks is worthwhile before consid-
ering further intervention. If 10 mg/day is not effective, an 
increase to 20 mg/day should be considered.69,70
Mirtazapine
The antidepressant activity of mirtazapine is a result of 
enhanced serotonergic and noradrenergic neurotransmission 
through blockade of presynaptic α2-adrenergic autorecep-
tors and heteroreceptors and postsynaptic 5-HT2 and 5-HT3 
receptors.71,72 No influence on serotonin or noradrenaline 
reuptake was observed.73,84 Mirtazapine has low affinity for 
central and peripheral dopaminergic and muscarinic recep-
tors, and high affinity for H1 receptors.83,84
Following oral administration, mirtazapine is rapidly 
absorbed, but the absolute bioavailability is moderate 
(see Table 2).73 The drug is nonspecifically and reversibly 
bound to proteins and possess a high distribution volume.75,86 
Metabolism is mediated by CYP1A2, CYP2D6, and 
CYP3A4.75,87 Demethylmirtazapine is the active metabolite, 
but its   exposure in the human body is three times lower 
compared with the parent drug.74
Low inhibitory effects of mirtazapine on major CYP 
isoenzymes were reported in vitro.83,88 No significant interac-
tions with the CYP2D6 substrates amitriptyline, clozapine, 
olanzapine, and risperidone were observed.90–92 In contrast, 
plasma concentrations of mirtazapine were reduced after 
concomitant administration of the CYP3A4 inducers 
carbamazepine87,90 and phenytoin.75 Moreover, mirtazapine 
disposition was affected by fluvoxamine and, to a lesser 
extent, by paroxetine.76,77 Coadministration of cimetidine 
(an inhibitor of CYP3A4, CYP1A2, and CYP2D6) increased 
mirtazapine plasma concentrations significantly, requiring 
dose adjustment.78 An additive sedative effect was observed 
with diazepam. Moreover, patients should be advised to avoid 
alcohol while taking mirtazapine.83,87
The drug is predominantly excreted in the urine and 
feces.87,89 The activity is prolonged by the circulation of the 
parent compound.87,89 High clearance values indicate renal 
tubular secretion.83,87,89 The elimination rate is strongly 
affected by CYP2D6 polymorphism.79,80 Steady state is 
reached in less than a week.81
In the therapeutic range, mirtazapine shows linear phar-
macokinetics.99 Nicotine may decrease plasma mirtazapine 
Table 3 Risk factors which may influence the pharmacokinetics of newer antidepressants
Drug Factors that may require dose adjustment
Escitalopram Dose adjustment recommended in patients with impaired hepatic function
Mirtazapine Age (elderly), hepatic impairment, caution in patients with moderate or severe renal insuficiency
Bupropion Gender; caution in elderly, and those with renal and hepatic impairment. 
Venlafaxine/Desvenlafaxine Renal and hepatic impairment 
If creatinine clearance is # 30 mL/min dose adjustment for venlafaxine recommended
Duloxetine Hepatic impairment, neccessary dose adjustment. 
Gender, age, nicotine and race – monitor adverse effects, dose adjustment if necessary
Milnacipran Caution in severe hepatic and moderate to severe renal impairment
Reboxetine Elderly require lower starting doses 
Caution in renal and hepatic dysfunction
Agomelatine Caution in patients with hepatic impairment; lack of data about other effectsNeuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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levels, and smokers may require increased doses.82 In contrast, 
mirtazapine plasma levels are increased in the elderly,91,100 as 
well as in patients with hepatic impairment,87 and dose reduc-
tion should be considered in both groups. Mirtazapine expo-
sure in patients with severe or moderate renal insufficiency 
is increased compared with healthy controls.83 Although 
there are no differences in reported adverse effects,102 the 
drug should be used with caution in these patients.84 Gender 
affects mirtazapine plasma levels, but the changes are not 
clinically important (see Table 3).101
The efficacy of mirtazapine in treatment of patients 
with moderate to severe MDD was reported in several 
studies.104–106 Short-term studies revealed similar efficacy for 
mirtazapine and amitriptyline.107–109 Moreover, mirtazapine 
had a longer time to relapse than amitriptyline during the 
first 20 weeks (see Table 1).85
Furthermore, mirtazapine showed similar or greater 
efficacy than citalopram, fluoxetine, paroxetine,   sertraline, 
duloxetine, fluvoxamine, and reboxetine.79,111–114 In a 
  meta-analysis of 25 randomized, controlled trials, mir-
tazapine showed a faster onset of action than SSRIs and 
was superior for short-term (two-week) response and 
remission rates, but the differences were not significant 
at the end of acute-phase treatment (6–12 weeks).86 The 
efficacy of mirtazapine and venlafaxine were similar in 
patients with severe depression characterized by melan-
cholic features.87
Mirtazapine was generally well tolerated in patients with 
MDD, with a lower frequency of side effects compared with 
placebo (see Table 1).84,96,105 Sedation, especially at low dose, 
and weight increase may be due to H1-receptor blockade.105 In 
a long-term treatment study, weight gain was the only more 
frequent side effect with mirtazapine than placebo, whereas 
blood pressure and heart rate were similar.83,110,117
Compared with amitriptyline, mirtazapine had fewer 
adverse events and less need for discontinuation of treatment 
due to an adverse event.83,110 Dry mouth, vertigo, and weight 
increase were as frequent as with TCAs, but seizures were 
less frequent.22,84
Discontinuation rates due to adverse events for mirtazap-
ine and SSRIs were similar. Mirtazapine was associated with 
significantly less insomnia, sexual dysfunction, and nausea 
than SSRIs, but with significantly more weight gain, dry 
mouth, fatigue, and excessive somnolence.88 Adverse effects 
such as increased salivation and weight gain were more 
frequent with mirtazapine compared with venlafaxine but 
sweating, constipation, increased sexual desire, and weight 
loss were more common with venlafaxine.116
Mirtazapine is used as a single agent, or in combina-
tion with SSRIs or venlafaxine. The recommended dose is 
15–45 mg/day, and it is generally given as a single dose in 
the evening.46
Bupropion
Bupropion is an atypical antidepressant, probably a selective 
inhibitor of noradrenaline and dopamine reuptake. Bupropion 
and its metabolites are slightly more potent inhibitors of 
dopamine than of noradrenaline reuptake, and do not affect 
the release or transport of other neurotransmitters, or have 
appreciable affinity for postsynaptic receptors including his-
tamine, α-adrenergic, serotonin, dopamine, or acetylcholine 
receptors.89,90
Bupropion is available in three oral formulations, 
ie, immediate-release (IR), sustained-release (SR), and 
  extended-release (XR).91 Absorption rates vary between the 
formulations, but there is no significant difference in the 
extent of absorption.120 Food does not affect absorption, 
which is at least 87% of an administered dose.120 Pharmacoki-
netics are linear in the therapeutic range (see Table 2).120,121
Bupropion is extensively distributed and bound to plasma 
proteins.121 Following hepatic metabolism via CYP2B6, 
three active metabolites, ie, hydroxybupropion, threohyd-
robupropion, and erythrohydrobupropion are formed.92,93 
Hydroxybupropion and threohydrobupropion possess about 
50% of the activity of the parent drug123 and their plasma 
concentrations are 4–7-fold and ∼5-fold higher than bupro-
pion, respectively.
Major effects of CYP2B6 genetic polymorphisms on 
the pharmacokinetics of bupropion have not been shown.94 
However, concomitant administration of CYP2B6 inducers, 
such as carbamazepine, lopinavir, and ritonavir, decreased 
bupropion plasma levels.90,95,96
Bupropion and hydroxybupropion may have a low 
potency for inhibition of CYP2D6.123 Coadministration of 
bupropion with the CYP2D6 substrates desipramine and 
venlafaxine resulted in increased levels of the substrates.90,97 
A case of severe bradycardia was related to the addition of 
bupropion to metoprolol.98 Therefore, low doses should be 
used, and dose monitoring should be considered following 
concomitant administration of bupropion and CYP2D6 
substrates with a narrow therapeutic range.90
The activity of bupropion is prolonged as a result of slow 
elimination of metabolites.121 Steady-state concentrations are 
reached after 7–10 days.121 Renal excretion is predominant, but 
the drug and its active metabolites cross the blood-brain barrier 
and placenta, and are also excreted in human breast milk.120Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The pharmacokinetic properties of bupropion are probably 
not influenced by nicotine.99,100 However, the effect of gender 
is unclear due to controversial findings.129–131 Bupropion SR is 
metabolized more rapidly in children compared with adults,121 
and the elderly are at risk of accumulation of the drug and its 
metabolites.101 Slower elimination of bupropion was observed 
in patients with renal impairment,102 and high variability in 
pharmacokinetic parameters was observed in patients with 
hepatic impairment. Therefore, bupropion should be used 
with caution in these groups (see Table 3).121
Bupropion was shown to be more efficacious than pla-
cebo. Improvement in primary and secondary outcomes were 
observed after 6–8 weeks with all bupropion formulations in 
adults with moderate to severe depression.103,104 ,120
Bupropion IR showed similar efficacy to nortriptyline,105 
amitriptyline,106 and fluoxetine.107 No significant differences 
in efficacy were observed with bupropion SR and sertraline 
after 8–16 weeks139–141 or fluoxetine.108 In the elderly, bupro-
pion SR and paroxetine showed similar efficacy.109 There 
were no significant differences between bupropion XR and 
escitalopram110 or venlafaxine XR111,112 in terms of primary 
or secondary outcome measures. After switching from cit-
alopram, bupropion SR was as effective as sertraline and 
venlafaxine XR.113 The drug was as effective as buspirone 
in augmentation of citalopram (see Table 1).114
Different formulations of bupropion have similar toler-
ability profiles and are generally well tolerated in adults and 
the elderly.120 Most adverse events associated with bupropion 
are mild to moderate in severity (see Table 1).120,134,135
Allergic reactions to bupropion occur rarely but, if symp-
toms arise, drug discontinuation should be advised.115,120 The 
risk of seizures is dose- but not formulation-dependent.120 
Rate of seizures was 0.1% for doses of 100–300 mg/day, 
and increased to 0.4% at doses of 300–450 mg/day.120,125,149 
Adverse events resulting in discontinuation of therapy were 
agitation, headache, nausea, and rash, which occurred at a rate 
of approximately 5%–11% with all bupropion products.149
Compared with nortriptyline, bupropion was associated 
with significantly fewer adverse events such as dry mouth, 
somnolence, and tachycardia.136 Generally, the tolerability 
profiles of bupropion and SSRIs are similar, although bupro-
pion is associated with more headache and dry mouth.115,120 
However, sexual dysfunction following SSRIs is not a problem 
with bupropion,151 and lower rates of somnolence and diarrhea 
are associated with this agent.151 Similar incidences of adverse 
events were reported for bupropion and venlafaxine.145
The administration of bupropion has certain advantages, 
such as a greater reduction in severity of symptoms and fewer 
adverse events.148 Bupropion is indicated in the treatment of adult 
patients with major depression but is not approved for use in 
pediatric patients.149 The recommended initial doses are 100 mg 
of bupropion IR twice daily, 150 mg of bupropion SR once daily, 
and 150 mg of bupropion XR once daily.115,120 The   maximum 
recommended dose is 450 mg/day for IR (150 mg three times 
daily) and XR (450 mg in the morning) formulations, or 400 
mg/day of bupropion SR (200 mg twice daily).120,152
Venlafaxine and desvenlafaxine
Venlafaxine probably inhibits serotonin uptake only in low 
doses, whereas both serotonin and noradrenaline uptake are 
inhibited following high doses.115 The drug does not possess 
significant affinity for 5HT1A, 5HT2A, D2, muscarinic, or α1- or 
α2- receptors, and does not inhibit MAO.116,153 Desvenlafaxine 
(O-desmethylvenlafaxine), the major metabolite of venlafax-
ine, has similar potency for the inhibition of serotonin and 
noradrenaline uptake.153
Following oral administration of venlafaxine, absorption 
starts after approximately 20 minutes and is completed within 
three hours for venlafaxine IR and for desvenlafaxine.116,117 
Venlafaxine XR is absorbed more slowly, but the extent of 
absorption is similar between formulations.156
The drug is widely distributed in the body, with low protein 
binding and a high volume of distribution (see Table 2).118,119 
Following oral absorption, venlafaxine undergoes extensive 
first-pass hepatic metabolism, where conversion to the active 
metabolite, desvenlafaxine, occurs via demethylation.157 
This reaction is mediated by CYP2D6.120 Desvenlafaxine 
is further metabolized by CYP3A4.122 Other metabolic 
pathways for venlafaxine include N-demethylation which is 
probably mediated by CYP3A4.157 CYP2C9 and CYP2C19 
isoenzymes may also be involved in the metabolic pathways 
of both drugs.121
In contrast with desvenlafaxine, the CYP2D6 genetic 
polymorphism has a significant influence on venlafaxine 
pharmacokinetics.122 Both drugs may have low potential 
for drug interactions, because of low protein binding and a 
relatively weak inhibitory effect on CYP isoenzymes.90,123 
Nevertheless, increased plasma levels of imipramine, its 
metabolite desimipramine,124 and risperidone were associ-
ated with concomitant administration of venlafaxine.125 
Furthermore, diphenhydramine may alter the disposition of 
venlafaxine via inhibition of CYP2D6.126 CYP3A4 inducers 
may enhance the clearance rate of desvenlafaxine.122
Venlafaxine and desvenlafaxine are primarily excreted 
via the renal route.157,127 About 29% of a venlafaxine dose is 
excreted as the active metabolite.156,128 Both venlafaxine and Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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desvenlafaxine are rapidly eliminated, and steady-state plasma 
concentrations are reached within three days. Both drugs show 
linear pharmacokinetics in the therapeutic range.157
Age and gender differences are not clinically significant 
and require no dose adjustment for either drug.129   Disposition 
of venlafaxine and desvenlafaxine may be affected by 
renal impairment, and a reduction in venlafaxine dose is 
recommended for patients with creatinine clearance rates 
,30 mL/min.157,166 Moreover, due to altered metabolism, 
patients with mild to moderate hepatic impairment require 
dose adjustment of venlafaxine and desvenlafaxine (see 
Table 3).157
Superior efficacy of venlafaxine compared with placebo 
and efficacy similar to that of the TCAs in major depression 
was reported.22,130,131 However, venlafaxine was superior to 
TCAs in treatment-resistant depression.170 Controversial 
reports exist concerning the relative efficacy of venlafaxine 
and SSRIs. Comparison of venlafaxine with sertraline and 
escitalopram showed similar efficacy in the treatment of 
severe depressive disorders.76,80,132 Comparable efficacy has 
also been reported for venlafaxine, fluoxetine, paroxetine, 
and fluvoxamine.22,133 However, some authors observed 
superior efficacy of venlafaxine compared with duloxetine, 
fluoxetine, fluvoxamine, paroxetine, and reboxetine (see 
Table 1),79,134,135 while others found only increased efficacy 
compared with fluoxetine among the second-generation 
antidepressants.136 Higher remission rates were observed with 
venlafaxine compared with SSRIs and placebo.172 Long-term 
venlafaxine treatment was effective in reducing relapse after 
a major depressive episode.170
Despite the conflicting evidence, venlafaxine may be 
a cost-effective alternative to fluoxetine and amitriptyline 
when used as first-line therapy.137 Venlafaxine XR is also 
probably one of the best alternatives for patients who do not 
benefit from SSRIs.46,172 Overall response and remission rates 
in major depression were significantly better with desvenla-
faxine 50–100 mg compared with placebo.138
Venlafaxine is better tolerated than TCAs, but may cause a 
broader array of adverse events, such as dry mouth, constipa-
tion, increased pulse, and increased heart rate compared with 
the SSRIs.46,139 The blood pressure increase seems to be dose-
dependent, and ranges from 2% at doses of 75–150 mg/day 
to 10% for 300 mg/day.22,140,178 Discontinuation syndrome, 
characterized by nausea, insomnia, chills, irritability, and 
paresthesias may occur when venlafaxine is stopped abruptly 
(see Table 1). This syndrome may be suppressed by switching 
to fluoxetine or tapering venlafaxine prior to withdrawal.140 
Furthermore, overdose with venlafaxine may be more serious 
than with the SSRIs.46,141 Tolerability is dose-dependent and 
may be improved by slower titration to higher doses.142
Desvenlafaxine has an acceptable safety and   tolerability 
profile.143 A strong dose-response effect on tolerability 
was reported, but both 50 mg and 100 mg doses were 
well tolerated.144,177 Discontinuation rates due to adverse 
events were similar to those with placebo. The most com-
mon adverse event was transient mild to moderate nausea. 
Changes in mean blood pressure were small but statistically 
significant. Erectile dysfunction in man and anorgasmia in 
women were the most common sexual adverse events.144
The usual dose of venlafaxine IR is 75–375 mg/day and 
75–225 mg/day for venlafaxine XR.46 With rapid venlafaxine 
dose escalation up to 375 mg/day, onset of efficacy can be 
achieved after only one week.145 Use of higher doses may also 
improve response in treatment-resistant depression. However, 
higher venlafaxine doses (300–375 mg/day) were associated 
with poorer tolerability.182 The usual dose of desvenlafaxine 
ranges from 50–100 mg once daily, although doses higher 
than 50 mg showed no evidence of better efficacy.46,184
Duloxetine
Duloxetine is an inhibitor of serotonin and noradrenaline 
reuptake, with more than 100-fold greater potency compared 
with venlafaxine.146 Duloxetine has low affinity for D2, 
serotonin, α1- and α2-adrenergic, muscarinic, H1, and opioid 
receptors. Duloxetine does not inhibit gamma-amino butyric 
acid, choline transporters, MAO-A or MAO-B.187
Duloxetine is absorbed within six hours following oral 
administration.147 This process may be delayed by food 
and decreased by evening administration.148 The drug has 
high protein binding and a high volume of distribution 
(see Table 2).149,150
Extensive metabolism, predominantly via CYP1A2, 
to a lesser extent via CYP2D6, and at a very low rate 
via CYP2C9,151,152 has been reported, but the metabolites 
have no significant activity.153 Duloxetine is a moderate 
CYP2D6 inhibitor and may inhibit its own metabolism154,155 
as well as the metabolism of CYP2D6 substrates, such as 
desimipramine.90,195 The inhibition or induction of CYP1A2 
is not clinically important , and coadministration of dulox-
etine with CYP1A2 substrates does not necessitate their dose 
adjustment.193 However, potent inhibitors of CYP2D6 and 
CYP1A2 may result in enhanced duloxetine concentrations 
and a need for dose adjustment.191,193
Due to high protein binding, duloxetine may displace 
other extensively protein-bound drugs, such as warfarin.191 
Elimination of the drug is rapid and primarily via urine and Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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feces.192 Steady state is reached in three days.190 Duloxetine 
has linear pharmacokinetics in the therapeutic range.194
Female gender and nicotine use have been associated 
with higher duloxetine plasma levels.196 Hispanic patients 
had a higher volume of distribution and delayed   absorption 
compared with non-Hispanics.196 Clearance decreases with 
increasing age, although this effect is small.196 Hepatic 
impairment decreases the clearance of duloxetine, and dose 
adjustment is necessary in patients with liver disease (see 
Table 3).156
At doses of 40–120 mg/day, duloxetine shows   superior 
efficacy compared with placebo in short-term studies 
(#15 weeks).198–201 The efficacy of duloxetine in the treat-
ment of painful somatic vegetative symptoms in patients with 
MDD is questionable.157,158
Duloxetine had better efficacy than paroxetine or 
fluoxetine only in patients with severe depression (see 
Table 1).159 The drug showed no significant difference in 
efficacy compared with venlafaxine,160 but a lower risk 
of increased blood pressure and fewer discontinuation 
symptoms when treatment was stopped.204,161 Compared 
with escitalopram, similar onset and efficacy of duloxetine 
(60–120 mg/day) has been observed.162,163 In contrast, a 
meta-analysis reported that escitalopram, mirtazapine, 
sertraline, and venlafaxine were significantly more effica-
cious than duloxetine.79
Generally, duloxetine is well tolerated both in short-term 
and long-term treatment of MDD (see Table 1).179,191,199,201 
The incidence of most common side effects may be dose-
dependent.164 Long-term treatment has a minimal effect on 
body weight,165 whereas short-term treatment is associated 
with modest effects on blood pressure and heart rate, no clini-
cally significant effect on Electrocardiogram profiles,166 an 
increased incidence of sexual dysfunction,167 and an increased 
risk of higher serum transaminase levels.209
The safety and tolerability profile of   duloxetine 
40–120 mg/day is similar to that of paroxetine 
20 mg/day.168 However, duloxetine is less well tolerated 
than escitalopram.207,208 Patients on duloxetine experience 
higher rates of insomnia and constipation.207 Furthermore, 
Cipriani et al reported poorer tolerability of duloxetine 
compared with sertraline.67 Higher discontinuation rates 
were observed with duloxetine due to adverse events 
compared with venlafaxine. Nausea and dizziness were 
more frequent in patients on duloxetine, while patients on 
venlafaxine experienced significantly greater elevation of 
systolic blood pressure.204
The usual starting dose is 40 mg/day (20 mg twice daily) 
to 60 mg/day (30 mg twice daily or 60 mg once daily) in the 
US and 60 mg once daily in the European Union.191
Milnacipran
Milnacipran inhibits noradrenaline and serotonin uptake 
at presynaptic sites.169 Despite the high affinity for both 
serotonin and noradrenaline transporters, noradrenaline 
reuptake is preferentially blocked.170 Postsynaptic cholin-
ergic, adrenergic, H1, D2, and serotonergic receptors are not 
affected.171,172
Following oral administration the onset of absorption 
is delayed.173 Bioavailability is high and not affected by 
food.174,218 Milnacipran has low protein binding and extensive 
distribution in the body.219,174 The drug undergoes oxidative 
biotransformation via CYP3A4 and conjugation.219 Only 
one of three metabolites has pharmacologic activity, but the 
concentrations are ,1% of the parent compound. The risk 
of pharmacokinetic drug-drug interactions may be low.175,219 
Moreover, induction or inhibition of CYP2D6 or CYP2C19 
has no significant effect on milnacipran.175
Due to potential pharmacodynamic interactions, mil-
nacipran is contraindicated in patients receiving MAOIs. 
Concomitant administration of drugs that may influence 
serotonin metabolism, such as tramadol, triptanes, and 
linezolid, is not recommended or requires caution due to 
potential serotonin syndrome. Coadministration with digoxin 
may result in potentiation of hemodynamic effects, whereas 
coadministration with adrenaline and noradrenaline may 
be associated with paroxysmal hypertension and possibly 
arrhythmia.218
Milnacipran elimination is rapid and predominantly 
renal.218,219 Steady-state concentrations are reached within a 
few days.215,221 The drug shows linear pharmacokinetics over 
the therapeutic dose range (see Table 2).218
Age and gender influence milnacipran plasma   levels 
but dose adjustment is not necessary.218 Milnacipran 
should be administered with caution in patients with 
severe hepatic or moderate to severe renal impairment (see 
Table 3).176,215,218,220
Milnacipran 50 mg was significantly more effective than 
placebo in the treatment of MDD.176,177 Comparison of mil-
nacipran with other antidepressants, such as SSRIs and TCAs, 
demonstrated no significant differences in clinical response or 
remission rates in the acute phase.178,179 Cipriani et al reported 
better scores for mirtazapine, escitalopram, venlafaxine, 
sertraline, and citalopram, than for milnacipran. In contrast, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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milnacipran scored better than bupropion, duloxetine, fluvox-
amine, paroxetine, fluoxetine, and reboxetine.67
Milnacipran is generally well tolerated (see Table 1).180,226 
Milnacipran may be superior to TCAs and SSRIs in terms 
of need for premature treatment withdrawal due to adverse 
events. Patients who experienced adverse effects from other 
antidepressants in the acute phase of treatment may benefit 
from this drug.228
Cipriani et al reported better tolerability scores for 
  escitalopram, sertraline, bupropion, and citalopram com-
pared with milnacipran. In contrast, milnacipran scored 
better than mirtazapine, fluoxetine, venlafaxine, duloxetine, 
  fluvoxamine, paroxetine, and reboxetine.67
The usual dose range for milnacipran is 100–200 mg/day.46 
Titration of the dose is recommended. The initiation dose 
should be 12.5 mg on the first day and 12.5 mg twice daily 
on the second and third days, 25 mg twice daily on the fourth 
to seventh days, and 50 mg twice daily thereafter. Based on 
individual response, the dose should be increased to 100 mg 
twice daily.218
Reboxetine
Reboxetine is a potent, selective, and specific noradrenaline 
reuptake inhibitor, with negligible affinity for muscarinic, 
H1, α1, and D2 receptors.180
Reboxetine has two chiral centers, but only the (R,R)-(-)- 
and (S,S)-(+)-enantiomer is present in the marketed 
product. Some studies suggest that both the therapeutic 
and adverse effects are related predominantly to (S,S)-(+)-
reboxetine.181
Reboxetine is absorbed rapidly and almost completely 
after oral administration.182,183 Food delays but does not influ-
ence the extent of absorption (see Table 2).184 Reboxetine is 
extensively bound to plasma proteins and has a moderate dis-
tribution volume compared with other antidepressants.231–233 
Metabolism occurs principally via CYP3A4.231 Each 
enantiomer is metabolized to the primary metabolite 
O-  desethylreboxetine, and three other   metabolites.185 Rebox-
etine is probably not an inhibitor of CYP isoenzymes.186,231
The drug has a moderate half-life and low clearance.231,232 
Reboxetine exhibits linear pharmacokinetics in the therapeu-
tic range.231 After multiple doses, steady state is achieved 
within four days.231
Ethnicity seems to influence reboxetine pharmacokinet-
ics but dose adjustment is not necessary.186 Plasma levels are 
higher and more variable in elderly patients, and therefore 
treatment with reboxetine should be initiated at a lower 
dose.187,188 The elimination rate of reboxetine decreases as renal 
function declines.189 Elimination is also slower in patients with 
hepatic dysfunction, but the degree of dysfunction does not 
affect reboxetine pharmacokinetics (see Table 3).190
In short-term studies (4–6 weeks) reboxetine showed 
superior efficacy compared with placebo in primary and 
secondary outcomes.242–244 Overall, reboxetine scored sig-
nificantly   better in mean responder rate and relapse rates 
compared with placebo (see Table 1).191,192,242   Compared 
with imipramine, the efficacy of reboxetine was similar 
in adults193 and elderly patients,194 but reboxetine had 
significant   advantages in the treatment of melancholic 
patients.195 Similar efficacy of reboxetine and fluoxetine 
was reported, but   reboxetine was more effective in a sub-
group of severely depressed patients.196,197 Moreover, social 
functioning was better in patients who achieved remission 
with reboxetine.250
Nevertheless, Cipriani et al suggested that reboxetine was 
significantly less effective than bupropion, citalopram, dulox-
etine, escitalopram, fluoxetine, fluvoxamine, milnacipran, 
mirtazapine, paroxetine, sertraline, and venlafaxine.79
The drug showed a good safety and tolerability profile 
(see Table 1).242 Reboxetine and imipramine had similar toler-
ability in adults and the elderly. Frequency of discontinuation 
due to adverse events was lower in the reboxetine group, 
whereas cumulative risk of hypotension, dry mouth, and 
tremor was significantly higher in the imipramine group.247 
Reboxetine patients had a lower risk of serious adverse 
events, adverse event-related withdrawals, and treatment-
related adverse events.248 The overall score of reboxetine for 
safety and tolerability was better than TCAs.
The adverse event profile of reboxetine is different to 
that of the SSRIs. Patients on reboxetine experienced less 
agitation, nervousness, anxiety, and gastrointestinal events 
compared with those on fluoxetine. Reboxetine was not 
associated with an increased risk of seizures, orthostatic 
hypotension, or cardiotoxicity,250 but had poorer tolerability 
than other antidepressants, including bupropion, citalopram, 
escitalopram, fluoxetine, and sertraline.79
Nevertheless, reboxetine is considered safe when admin-
istered at doses of 8–10 mg/day to adult (18–65 years) and 
at 4–6 mg/day to elderly (.65 years) patients.242
The recommended therapeutic dose for adults is 4 mg twice 
daily (8 mg/day). The dose can be increased to 10 mg/day 
after three weeks if there is an inadequate clinical response. 
The recommended dose for the elderly (.65 years) is 2 mg 
bid (4 mg/day) and, if necessary, the dose can be increased Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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to 6 mg/day. The same strategy is used for patients with renal 
impairment or moderate to severe hepatic insufficiency.242
Agomelatine
Agomelatine is an antagonist of serotonin 5HT2B and 5HT2C 
receptors and a potent agonist of melatonergic MT1 and MT2 
receptors.198,199 Serotonin outflow is not affected, but due to 
5HT2C antagonism, overflows of dopamine and noradrena-
line are produced in the frontal cortex.200 The drug received 
marketing authorization for Europe in 2009 and is awaiting 
Federal Drug Administration approval in the US.
After oral administration, more than 78% of the dose is 
rapidly absorbed.254 Agomelatine is highly protein-bound 
and moderately distributed (see Table 2).253
Metabolism to inactive hydroxylated and demethylated 
metabolites is mediated primarily by CYP1A2 and to a less 
degree by CYP2C9 and CYP2C19.201 There is a lack of data 
about potential drug interactions, and this requires further 
investigation. The metabolites are excreted mainly in urine 
and feces.253,254 Elimination rate is very fast and steady-state 
concentrations are reached rapidly.253
The bioavailability of agomelatine may be increased in 
women and reduced in smokers.255 There are limited data 
about the pharmacokinetics of agomelatine in the elderly and 
in patients with renal impairment. Nevertheless, systemic 
exposure to agomelatine is increased in patients with hepatic 
impairment (see Table 3).253,255
Agomelatine significantly improved response rates and 
time to first response compared with placebo in 212 out-
patients who received 25 or 50 mg/day.202 Moreover, the onset 
of response with agomelatine was faster (two weeks) com-
pared with paroxetine (four weeks).203 Higher efficacy than 
placebo was observed in patients with severe depression and 
efficacy increased with increasing severity of depression.204 
Agomelatine 50 mg/day and venlafaxine 75–150 mg/day had 
similar response rates after 6–12 weeks.205,206
Agomelatine was generally well tolerated, with a good 
safety profile (see Table 1).256 Compared with venlafaxine, 
the agomelatine treatment group experienced less frequent 
sexual dysfunction and orgasmic dysfunction.259 Safety 
profile was generally better compared with current stan-
dard treatments, including absence of serotonin syndrome, 
weight gain, and a low incidence of sexual dysfunction 
and gastrointestinal adverse effects.252 Abrupt cessation 
of agomelatine was not associated with discontinuation 
symptoms.207
Despite encouraging results for the safety and toler-
ability of agomelatine, there is still a lack of data regarding 
its efficacy which requires further investigation. The usual 
initiating dose is 25 mg/day which may be increased if neces-
sary to 50 mg/day.253
Aripiprazole
Aripiprazole is an atypical antipsychotic approved as a 
adjunct treatment for MDD. The probable mechanism 
of antidepressant action is partial agonism at D2, D3, 
and 5-HT1A receptors and antagonistic activity at 5-HT2A 
receptors. Moderate affinity was also found for D4, 
5-HT2C, 5-HT7, α1-adrenergic, and H1 receptors, whereas 
the activity at muscarinic and cholinergic receptors was 
minimal.208
Aripiprazole is well absorbed following oral   administration. 
Food prolonged the time of absorption for approximately 
three hours but did not affect extent of absorption (see Table 
2). The drug is almost completely bound to plasma proteins. 
Following metabolism mediated by CYP3A4 and CYP2D6, 
the active metabolite, dehydroaripiprazole, is formed. Genetic 
polymorphism of CYP2D6 has a significant influence on 
aripiprazole plasma levels, and poor metabolizers have an 
approximately 60% increased exposure to the drug. Aripip-
razole has low inhibitory potential for CYP450 isoenzymes. 
No relevant interactions were observed after coadministra-
tion of the drug with SSRIs and venlafaxine. In contrast, 
concomitant administration of CYP3A4 inducers may require 
increased doses of aripiprazole whereas concomitant admin-
istration of CYP2D6 or CYP3A4 inhibitors may require dose 
reduction for aripriprazole.262
Aripiprazole is eliminated slowly, therefore takes about 
two weeks to reach steady state. Urine and feces are the main 
elimination routes.262 Age, race, gender, smoking status, and 
hepatic and renal function showed no clinically relevant 
effects on aripiprazole pharmacokinetics.262
A meta-analysis of clinical efficacy trials of aripipra-
zole (2–20 mg/day) revealed increased response rates of 
8% and increased remission rates of 10% when the drug 
was used as adjuvant antidepressant medication compared 
with placebo in patients with MDD (see Table 1).209,210 
However, the absolute difference in the efficacy outcome 
between aripiprazole and placebo was relatively low, 
and therefore the clinical significance of the findings is 
debatable.211,212 Because augmentation is used in patients 
who have failed to respond to monotherapy, evaluation 
of clinical relevance is difficult and further studies are 
necessary.
The most common adverse effects of aripiprazole are 
presented in Table 1. Discontinuation of treatment due to Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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adverse effects was rarely observed, and no serious adverse 
effects were reported.263,264
The starting dose for adjunctive aripiprazole treatment 
should be 2–5 mg/day. If necessary, a weekly dose increase 
is recommended up to 15 mg/day. The drug is not approved 
for the treatment of patients with dementia-related psychosis 
or depressive pediatric patients.262 Further investigations with 
aripiprazole are necessary to establish its full potential in the 
treatment of MDD.
Emergence of new therapeutic 
agents
Vilazodone is a serotonin reuptake inhibitor and a par-
tial 5-HT1a agonist. This drug is currently under clinical 
  evaluation for the treatment of major depression and 
awaiting approval by the Federal Drug Administration. 
So far, results for the clinical efficacy of vilazodone in 
depressed patients have been conflicting. A large Phase II 
trial including more than 1000 depressed patients failed 
to show efficacy of the drug over placebo.213 In contrast, 
a Phase III trial which included 410 patients with MDD 
revealed superior efficacy of viladozone (10–40 mg/day) 
over placebo in primary and secondary outcomes within 
eight weeks.214 Vilazodone was well tolerated, and adverse 
effects were mild to moderate, including nausea, somno-
lence, diarrhea, and dizziness.
Serotonin, noradrenaline, and dopamine (triple) reuptake 
inhibitors are in process of development,215 and most are now 
in Phase II clinical trials.216 Some of these drugs (eg, DOV 
21947) show significantly higher efficacy compared with 
placebo and similar efficacy to citalopram.269 In contrast, lack 
of improved efficacy resulting in discontinued development 
(NS-2359) was also reported.217
Drugs that antagonize α2-adenoreceptors and suppress 
reuptake of serotonin or noradrenaline or both (S35966 and 
R226161) may have a faster onset of effect, and improve 
cognition and sexual function. However, adverse effects 
comprising increased arterial pressure and tachycardia were 
reported.218,219 ,267
Dual-acting serotonin reuptake inhibitors and H3 antago-
nists (eg, JNJ-2583867) may improve mood and cognitive 
impairment in depression and have a low risk of obesity. 
A possible disadvantage of these substances may be their 
wake-inducing action.220,267
Some emerging evidence suggests that several families 
of glutamate receptors may be potential targets for new 
antidepressants.267,269 CP-10-606, an N-methyl-D-aspartic 
acid antagonist, significantly improved depressive symp-
toms compared with placebo.269 There are some suggestions 
that positive allosteric modulators at α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor (AMPA) 
receptors may be useful in the clinical management of 
depression.267,269 However, clinical data on these agents are 
not yet available.269
Riluzole, a glutamate-modulating agent, approved for 
treatment of amyotrophic lateral sclerosis, showed antide-
pressant properties and was well tolerated.221,269 However, 
its role as monotherapy or augmentation of standard therapy 
remains to be established.
Metyrapone, an inhibitor of cortisol synthesis, 
may become a possible adjunctive agent for major 
  depression.269 Also, a strong antagonist of the Type II 
glucocorticoid receptor, mifepristone (RU486) was 
suggested as   adjunctive   treatment for psychotic depres-
sion.269 However,   pivotal Phase III studies of mifepristone 
in MDD with psychotic features have had discouraging 
results.269
Compliance
One of the major obstacles to effective management of 
depression is poor compliance.220 Sawada et al found 
that only 44.3% patients continued antidepressant treat-
ment after six months. Moreover, 63.1% patients who 
discontinued therapy did so without consulting their 
physicians.221
Reasons for treatment discontinuation are multifacto-
rial. Symptoms of depression such as poor concentration 
and motivation may predispose patients to noncompli-
ance. Early withdrawals are usually due to adverse events 
or lack of efficacy. However, later dropouts are usually 
due to patients feeling better or fearing drug addiction. 
Studies suggest men are more likely to discontinue anti-
depressant therapy than women following initial treatment 
efficacy.276
Choice of an adequate, effective, and well tolerated 
drug with optimal formulation, as well as effective com-
munication between patient and health professionals, 
are important for successful treatment. The newer, more 
selective   antidepressants may have better tolerability and 
hence better compliance.277 Moreover, drugs with a longer 
half-life and once-daily dosing schedules will improve 
patient compliance.276,277 Patients suggest that information 
about adverse events and likely duration of treatment may 
significantly improve compliance. Well informed patients 
are less likely to discontinue treatment and more likely to 
switch drug if necessary.222,223Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Conclusion
MDD is a complex disease and requires a multifaceted approach 
for research, diagnosis, and treatment.   Modern classes of anti-
depressants such as SSRIs, serotonin/  noradrenaline reuptake 
inhibitors, and noradrenaline/  dopamine reuptake inhibitors 
offer superior tolerability and safety over older medications 
like the TCAs and MAOIs. However, the choice among newer 
antidepressants is difficult, given that all of them showed more 
or less similar efficacy and good tolerability. Nevertheless, 
individual patient preferences related to adverse effect pro-
files and cost of treatment, as well as adjusting the regimen 
appropriately, may provide the best approach. If a single drug 
fails, combined treatment with antidepressants having differ-
ent modes of action may improve treatment efficacy. However, 
with such approach, the increased risk of interactions should 
be considered.
It is clear that there are substantial limitations in cur-
rent antidepressant pharmacotherapy and there is a need 
for new therapeutic approaches. Advances in understand-
ing the   neurobiology of depression have opened up a new 
era of investigations with novel therapeutic approaches and 
  compounds based on new mechanisms of action. Today, 
research is focused on a variety of targets such as the 
L-  arginine-nitric oxide-cyclic guanosine monophosphate 
pathway, the endocannabinoid system, sigma-1 recep-
tors, melatonin, 5-HT6 and 5-HT7 receptor antagonists, β3 
adrenergic antagonists, vasopressin receptor antagonists, 
and NK2 tachykinin receptor antagonists. Although the 
potential efficacy of these agents remains to be estab-
lished, the future of antidepressant treatment appears to 
be promising.
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